CD19+

Phase 1Biologic

SSt. Jude Children's Research Hospital

CD19+ is one of 2 biologic programs targeting Relapsed/Refractory B-cell Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Relapsed/refractory B-Cell MalignanciesNot yet recruiting

Relapsed/refractory B-Cell MalignanciesPhase 1

Not yet recruiting

Competition

Competitive Landscape

5 competitors in Relapsed/refractory B-Cell Malignancies

#DrugCompanyPhaseTrials

SYS6055

BBeijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd

Phase 1

1 2

CD19+

SSt. Jude Children's Research Hospital

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Acute Lymphoblastic Leukemia (ALL)

NCT03849651

Q4 2032

Phase 1Not yet recruiting

Relapsed/refractory B-Cell Malignancies

NCT07763938

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia (ALL)1 trial

TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT03849651·69 enrolled

Relapsed/Refractory B-cell Malignancies1 trial

A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT07763938·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CD19+. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD19+ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD19+. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSt. Jude Children's Research Hospital

CD19+

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2032

Trials by Indication[1]

Acute Lymphoblastic Leukemia (ALL)1 trial

Relapsed/Refractory B-cell Malignancies1 trial

References

Drug Info

Quick Facts

Related News